Ningxia Zhongke Biotechnology Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Ningxia Zhongke Biotechnology Co., Ltd. carries a market capitalization of 1.96B, placing it among publicly traded companies globally. Its enterprise value stands at 3.75B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.96B |
| Enterprise Value | 3.75B |
Share Statistics
Ningxia Zhongke Biotechnology Co., Ltd. currently has 684.88M shares outstanding.
| Shares Outstanding | 684.88M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 7.13, and the price-to-book ratio stands at -2.93.
| PE Ratio | N/A |
| PS Ratio | 7.13 |
| PB Ratio | -2.93 |
| P/TBV Ratio | -212.21 |
| P/FCF Ratio | 81.49 |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 8.37 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 32.17 |
Financial Position
Ningxia Zhongke Biotechnology Co., Ltd. maintains a current ratio of 0.20, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 953.90, indicating elevated leverage, while an interest coverage ratio of -2.53 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.20 |
| Quick Ratio | 0.04 |
| Debt / Equity | 953.90 |
| Debt / EBITDA | -2.45 |
| Interest Coverage | -2.53 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -11.94 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.10 |
Taxes
| Income Tax | -2.50M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Ningxia Zhongke Biotechnology Co., Ltd.'s stock has declined approximately -36.3029% over the past 52 weeks. The 50-day moving average sits at 2.99, while the 200-day moving average is 3.59.
| Beta (5Y) | N/A |
| 52-Week Price Change | -36.3029% |
| 50-Day Moving Average | 2.99 |
| 200-Day Moving Average | 3.59 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Ningxia Zhongke Biotechnology Co., Ltd. generated 447.41M in revenue and converted that into -284.94M in net income, yielding earnings per share of -0.48. EBITDA reached -197.18M, while operating income came in at -197.18M.
| Revenue | 447.41M |
| Gross Profit | -110.17M |
| Operating Income | -197.18M |
| Pretax Income | -328.46M |
| Net Income | -284.94M |
| EBITDA | -197.18M |
| EBIT | -197.18M |
| Earnings Per Share (EPS) | -0.48 |
Balance Sheet
Ningxia Zhongke Biotechnology Co., Ltd. holds 76.63M in cash and equivalents against 482.65M in total debt, resulting in a net debt position of 399.25M. Total book value stands at -1.09B, with working capital of -1.59B providing operational flexibility.
| Cash & Cash Equivalents | 76.63M |
| Total Debt | 482.65M |
| Net Debt | 399.25M |
| Equity (Book Value) | -1.09B |
| Book Value Per Share | -1.60 |
| Working Capital | -1.59B |
Cash Flow
After subtracting -39.15M in capital expenditures, free cash flow totaled -39.15M - equivalent to -0.06 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -39.15M |
| Free Cash Flow | -39.15M |
| FCF Per Share | -0.06 |
Margins
Ningxia Zhongke Biotechnology Co., Ltd. operates with a gross margin of -24.62, reflecting its pricing power and cost economics. The operating margin of -44.07 and net profit margin of -63.69 provide insight into operational efficiency.
| Gross Margin | -24.62 |
| Operating Margin | -44.07 |
| Pretax Margin | -73.41 |
| Profit Margin | -63.69 |
| EBITDA Margin | -44.07 |
Dividends & Yields
The company's payout ratio of -0.86 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.00 |
| Dividend Yield | N/A |
| Payout Ratio | -0.86 |
| Shareholder Yield | -11.63 |
| FCF Yield | 1.23 |
Stock Splits
Ningxia Zhongke Biotechnology Co., Ltd.'s most recent stock split took place on October 12, 2015 with a 2:5 split ratio.
| Last Split Date | 10/12/2015 |
| Split Ratio | 2:5 |
Scores
Ningxia Zhongke Biotechnology Co., Ltd. posts an Altman Z-Score of -1.20, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.20 |